The complexity of the cardio-renal link: taxonomy, syndromes, and diseases

Carmine Zoccali1, David Goldsmith2, Rajiv Agarwal3, Peter J. Blankestein4, Danilo Fliser5, Andrzej Wiecek6, Gultekin Suleymanlar7, Alberto Ortiz8, Ziad Massy9,10, Adrian Covic11, Alberto Martinez-Castelao12, Kitty J. Jager13, Friedo W. Dekker14, Bengt Lindholm15 and Gerard London16, EUnPEO REnal and Cardiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA)

1Nephrology, Dialysis and Transplantation Unit and CNR-IBIM Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy; 2Renal Unit, Guy’s and St Thomas’ NHS Foundation Hospital, King’s Health Partners, London, UK; 3Indiana University and VAMC, Indianapolis, Indiana, USA; 4Department of Nephrology, University Medical Center, Utrecht, The Netherlands; 5Department of Internal Medicine IV, Saarland University Medical Centre, Homburg/Saar, Germany; 6Division of Internal Medicine and Nephrology, Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland; 7Nephrology Division, Department of Medicine, Akdeniz University Medical School, Antalya, Turkey; 8Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Fundación Renal Irígo Alvarez de Toledo, Madrid, Spain; 9INSERM ERI-12 (EA 4292), Amiens, France; 10Amiens University Hospital and the Jules Verne University of Picardie, Amiens, France; 11Clinic of Nephrology, C. Parhon University Hospital, Gr. T. Popa University of Medicine and Pharmacy, Iasi, Romania; 12Hospital Universitario de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain; 13ERA–EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 14Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; 15Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden and 16INSERM U970, Hôpital Émile Pigeon, Paris, France

Bidirectional mechanisms exist that link diseases affecting the heart and kidney. This link is complex and remains poorly understood; therefore, charting the shared territory of cardiovascular (CV) and renal medicine poses major problems. Until now, no convincing rationale for delineating new syndromes existed. The multiple connections of the arterial system and the heart and kidney with other systems, from energy and protein balance to the musculoskeletal, clearly require special focus and rigorous framing. Nephrologists have yet to fully understand why the application of dialysis has had only limited success in halting the parallel burdens of CV and non-CV death in patients with end-stage renal disease. Cardiologists, intensivists, and nephrologists alike should settle whether and when extracorporal ultrafiltration benefits patients with decompenated heart failure. These sparse but interconnected themes spanning from the basic science–clinical transition phase to clinical science, epidemiology, and medical technology already form the basis for the young discipline of ‘CV and renal medicine’. Chronic kidney disease (CKD) is now recognized as a public health priority in economically developed and developing countries alike. Concern about CKD goes far beyond mere loss of renal function because the risk of fatal and non-fatal atherosclerotic complications in these patients is much higher than that of progressing to end-stage renal disease. From a diachronic perspective, CKD is a fundamental element of transitional epidemiology, an epochal change whereby chronic diseases have replaced communicable diseases as leading causes of death and disability. Because of the numerous functional relationships of the kidney with blood pressure and fluid volume control and with cardiovascular (CV) function in general, loss of renal function is one of the strongest triggers of high CV risk. Although the epidemiological burden of CKD at the population level is now well framed, the mechanistic nature of the relationship between CV and renal disease remains a complex, hitherto largely unresolved, issue.

THE COMPLEXITY OF THE CV–RENAL LINK

Independently of age, sex, background CV damage, and Framingham factors, the risk for CV death increases gradually as renal function deteriorates to be 3.4 times higher in patients with kidney failure than in individuals with normal glomerular filtration rate (GFR; > 60 ml/min per 1.73 m²) (Figure 1). This relationship is generally explained by assuming a causality chain starting from the kidney. Yet, the CV-renal link underlies complex reciprocal interorgan influences, whereby kidney disease may adversely affect the heart and the arterial system and vice versa.

Kidney International Supplements (2011) 1, 2–5

Mini review

http://www.kidney-international.org

© 2011 International Society of Nephrology
Severe CV disease can be triggered in experimental models by renal mass ablation. This intervention triggers left ventricular hypertrophy, fibrosis, and defective capillarization in the rat, as well as severe arterial damage with extensive inflammation, plaque formation, and a propensity to calcified lesions in the APO E–/E– mouse. These models support the hypothesis that left ventricular hypertrophy, defective myocardial oxygen supply, and severe arterial lesions commonly observed in CKD are consequences of reduced renal mass. On the other hand, the reverse possibility—that cardiac disease may engender the other—is well documented. In uninephrectomized rats, myocardial infarction triggers a marked rise in albumin excretion rate and a parallel increase in focal glomerulosclerosis, and both alterations are proportional to the myocardial necrosis area. Myocardial infarction in patients with coronary heart disease prompts a decline in the GFR of the same order observed in patients with primary renal diseases. In the earlier stages (NYHA I–II) of heart failure, patients exhibit an early, reversible, but ultimately permanent loss of the renal vasodilatory response to nitric oxide (NO)-generating agents. As heart failure intensifies in its severity into the congestive phase (NYHA III–IV), GFR becomes cardiac output dependent such that a moderate-to-severe reduction in GFR is typical in these patients. Bidirectional mechanisms exist that link diseases affecting the heart and the kidney. Activation of the sympathetic and renin–angiotensin–aldosterone systems, alterations in nitric oxide bioavailability, inflammation and overproduction of reactive oxygen species are established common pathophysiological pathways mediating clinical outcomes in cardiac and renal insufficiency. These pathways are causally implicated in the high risk of these conditions because therapies targeting the same pathways produce unquestionable beneficial effects in patients with either renal or CV diseases. Parallel aging of the CV system and of the kidney and the challenge of maintaining energy balance in the face of anorexia stimuli, inflammation, and oxidative stress is the obvious common soil of advanced cardiac and renal failure.
support the construct of this syndrome, remains largely unsupported. Indeed, there is no proof that such a coexistence has a synergistic effect on clinical outcomes, that is, an effect greater than that expected from the mere combination of the two risk factors. For example, proof that a synergism exists between inflammation and wasting in end-stage renal disease has been established recently, which supports the construct of the Malnutrition–Inflammation syndrome. Renal function does not add predictive value to clinical scores aimed at assisting prognosis in patients with heart failure and there is no evidence of biological and/or statistical interaction between renal function and other components of these scores. It is undisputable that a decline in renal function renders fluid volume control in decompensated heart failure problematic. However, antinatriuretic mechanisms are already operative in early heart failure when the GFR is still modestly or not affected, which points to a continuously operating interdependent process that allows for reciprocal fine-tuning of cardiac and renal function in heart diseases rather than to a later, threshold-exceeding event.

Treatment decisions
As to treatment decisions, in line with the general diktat that clinical monitoring should be comprehensive in severe systemic diseases, renal function measurement is recommended by current guidelines of heart failure. However, treatment of advanced heart failure remains guided by cardiorespiratory symptom, exercise tolerance, and hemodynamic considerations, rather than tailored on the basis of associated clinical conditions and renal failure.

Overall, the lack of robust anchoring of this syndrome to a precise clinical or pathophysiological rationale is reminiscent of the problems that emerged after the general proposition of the ‘metabolic syndrome’, an entity initially recognized and variously classified by major guideline developers and by the WHO. Indeed, a group of experts appointed by the same organization recently concluded that ‘metabolic syndrome is a concept … (that) may be considered useful as an educational concept, but with limited practical utility as a diagnostic or management tool’. New syndromic entities not supported by sufficient conceptual grounds should not be considered as neutral to the course of clinical research because these may have unpredictable effects on research orientation. Again, the metabolic syndrome can be taken as a case in point. Genetic epidemiology of the metabolic syndrome has become a much pursued research theme. Even though several meaningful associations between the individual components of the syndrome and various genes have been documented, as yet, no genetic factors that encompass all traits of the syndrome have been identified. This might not only simply reflect the lack of power of analyses performed so far but may also imply that this syndrome has no unifying basis.

Scoping questions
The ‘omics’ technology now provides unprecedented opportunities for a new system biology-based approach to the study of the cardio-renal link and for describing the dynamics of cardio-renal risk factors in the evolution of human diseases in an integrated view that can match the Guytonian paradigm. The dawn of new medicine is visible but time is needed to build up new clinical science based on system biology and for this science to reap dividends in terms of health benefits. As to the specifics of the cardio-renal link, the questions and the problems on the table are disparate and scoping these questions is important to identify research priorities. Although deciphering the interrelationship of endothelial dysfunction, sympathetic overactivity, and the renin–angiotensin system with CV and renal diseases, an issue in part in the first phase of translational (T1) research, will certainly take advantage of the application of new technologies, an understanding of the blood pressure-CV risk relationship in these diseases and the application of this knowledge into clinical practice are already on a track that may rapidly mature to inform clinical practice (T2–T3 phases). The multiple connections of the arterial system and the heart and the kidney with other systems, from energy and protein balance to the musculoskeletal system, clearly require special focus and proper framing. Lingering questions also remain in relation to the application of extracorporeal treatments in kidney and heart diseases. Nephrologists are yet to fully understand why the application of dialysis has had only limited success in halting the parallel burden of CV and non-CV death in end-stage renal disease patients, an observation pointing to an array of risk factors having broad effects on major biological systems rather than to effects restricted to the CV system. Finally, cardiologists, intensivists, and nephrologists alike should settle whether and when extracorporeal ultrafiltration benefits patients with decompensated heart failure. These are sparse but interconnected themes spanning from the basic science-clinical transition (T1) phase to clinical science (T2–3), epidemiology, and medical technology. We believe that it is important that investigators in the CV and renal area join their efforts to frame a common clinical research agenda. Herein, European Renal and CV medicine investigators pose a series of research questions on key issues of the CV-renal link that appear mature for entering the translational phase of research and/or whose answers may yield useful information to improve diagnosis, prognosis, and treatment of CV and renal diseases.

DISCLOSURE
AC has received consulting fees from Abbott Laboratories and received lecture fees from F. Hoffmann-La Roche, Amgen, and Fresenius Medical Care Holdings. AM-C has received consulting fees from Abbott Laboratories, Roche Spain, and Abbott Spain. AO has received grant support from the Spanish Government. AW has received consulting fees from Amgen, F. Hoffmann-La Roche, and Janssen-Cilag. AW has also received grant support from Astellas Pharma. DF has received funding from the EU. DG has received consulting fees and lecture fees from Shire, Genzyme, Novartis AG, Sandoz, Pfizer, and Fresenius Medical Care Holdings. FWD has received funding from Amgen and Baxter. GL has received consulting fees from Amgen and Sandoz. GL has also received lecture fees from Amgen, Sandoz, Genzyme, and Shire. PJB has received consulting.
fees from Medtronic and has received grant support from Ardenian and Novartis AG. RA has received consulting fees from Amgen, Abbott Laboratories, Merck, Affymax, Takeda Pharmaceutical Company, Daiichi Sankyo, Celgene, Watson Pharmaceuticals, and Rockwell Medical. RA has also received lecture fees from Abbott Laboratories, Merck, and Medscape. ZM has received lecture fees from Amgen, Shire, Genzyme, FMC, and Merck Sharp & Dohme. ZM has received grant support from Baxter, Amgen, FMC, Shire, and Genzyme. The remaining authors declared no competing interests.

REFERENCES

1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: a systematic review. BMC Public Health 2008; 8: 117.
2. Zoccali C, Kramer A, Jager KJ. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant 2010; 25: 1731–1733.
3. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659–663.
4. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Q 2005; 83: 731–757.
5. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073–2081.
6. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
7. Amann K, Wiest G, Zimmer G et al. Reduced capillary density in the myocardium of uremic rats—a stereological study. Kidney Int 1992; 42: 1079–1085.
8. Bro S, Bentzon JF, Falk E et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14: 2466–2474.
9. Massy ZA, Ivanovski O, Nguyen-Khoa T et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005; 16: 109–116.
10. van Dokkum RP, Eijkelkamp WB, Kluppel AC et al. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol 2004; 15: 3103–3110.
11. Hillge HL, van Gilst WH, Van Veldhuisen DJ et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003; 24: 412–420.
12. Magri P, Rao MA, Cangianello S et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 1998; 98: 2849–2854.
13. Cody RJ, Ljungman S, Covit AB et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int 1988; 34: 361–367.
14. Damman K, van DV, Navis G et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582–588.
15. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244–252.
16. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575–1581.
17. Lewis T. Paroxysmal dyspnoea in cardiorenal patients: with particular reference to ‘cardiac’ and ‘uremic’ asthma. Br Med J 1913; 29: 1417–1420.
18. Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592–2600.
19. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527–1539.
20. National Heart, Lung and Blood Institute (NHLBI) working group. Cardiorenal connections in heart failure and cardiovascular disease. 20-8-2004. http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-h-f-hd.htm. Accessed 20 December 2010.
21. Testani JM, Chen J, McCauley BD et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and cardiovascular disease. N Engl J Med 2004; 351: 2957–2964.
22. Besarab A, Horl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 2009; 14(Suppl 1): 22–33.
23. Keane WF. Metabolic pathogenesis of cardiorenal disease. Am J Kidney Dis 2001; 38: 1372-1375.
24. de Mutsert R, Groothorst DC, Axelson J et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23: 2957–2964.
25. Levy WC, Mozaffarian D, Linker DT et al. The Seattle heart failure model: prediction of survival in heart failure. Circulation 2006; 113: 1424–1433.
26. Lee DS, Austin PC, Rouleau JL et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290: 2581–2587.
27. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.
28. Grundy SM, Brewer Jr HB, Cleeman JI et al Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.
29. Simmons RK, Alberti KG, Gale EA et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 600–605.
30. Lusis AJ, Attie AD, Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat Rev Genet 2008; 9: 819–830.
31. Wheelock CE, Wheelock AM, Kawashima S et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol Biosyst 2009; 5: 588–602.
32. Lauer MS, Skaratlos S. Translational research for cardiovascular diseases at the National Heart, Lung, and Blood Institute: moving from bench to bedside and from bedside to community. Circulation 2010; 121: 929–933.
33. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782–1789.
34. Bart BA. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail 2009; 2: 499–504.
35. Shin JT, Dec GW. Ultrafiltration should not replace diuretics for the initial treatment of acute decompensated heart failure. Circ Heart Fail 2009; 2: 505–511.